Bristol Myers Squibb Company - רווח למניה ב-12 החודשים האחרונים BMY

Bristol-Myers Squibb (BMY) focuses on the global targeted therapy market, refreshing its portfolio through the acquisition of startups. Its status as a recognized innovator in immunology strengthens physician confidence. A year-over-year EPS (TTM) comparison confirms the business's resilience, where the value of 52.80 characterizes this level. However, the expiration of patents on key drugs is temporarily reducing the holding's overall margins.
Bristol-Myers Squibb - פילוחים אנליטיים ומדדי מפתח (BMY)

Bristol-Myers Squibb (BMY) resilience to market volatility is driven by stable demand for patented oncology and cardiovascular therapies. The profitability dynamics of this business are reflected in the 12-month YoY EPS trend, which smooths quarterly gaps via a rolling annual window. This metric measures the actual growth in net income per share while neutralizing reporting seasonality. Investors should note that even with a positive trend, high borrowing costs may exert pressure on capital margins.